Skip to main content

Advertisement

SpringerLink
Log in

Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro

  • Original Article
  • Published:
Clinical Oral Investigations Aims and scope Submit manuscript

Abstract

Objectives

Geranylgeraniol (GGOH) has been reported as a potential treatment option for bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ). The aim of this study was to analyze the effects of GGOH on endothelial progenitor cells (EPC) after bisphosphonate treatment in vitro.

Materials and methods

EPC were incubated with different nitrogen (N-BPs: ibandronate, pamidronate, zoledronate) and a non-nitrogen-containing bisphosphonates (NN-BP: clodronate) with and without GGOH. Cell viability was measured by MTT and PrestoBlue assay. Migration ability was analyzed with a Boyden and Scratch assay. Apoptosis rates were determined by colony-forming, Tunel and ToxiLight assays.

Results

Negative effects of N-BPs on EPC were shown in all tests without GGOH. The substitution of GGOH demonstrated significantly increased cell viability (MTT: p each N-BP ≤0.004; PrestoBlue: p each N-BP <0.001) and migration ability (Boyden: p each N-BP <0.001; Scratch: p each N-BP <0.001). Concerning the apoptosis rates, increased EPC colony densities (p each N-BP ≤0.009), decreased numbers of apoptotic cells in the Tunel assay (p each N-BP <0.001), and a decreased adenylate kinase release in the ToxiLight assay (p each N-BP ≤0.03) were observed. For the clodronate-treated cells, no significant differences could be detected with or without GGOH in any assay (p each N-BP/NN-BP >0.05).

Conclusions

GGOH cell treatment reversed the negative effects of bisphosphonates on EPC.

Clinical relevance

These findings support the hypothesis that systemic or local GGOH treatment might lead to new therapeutic strategies for BP-ONJ.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Walter C, Sagheb K, Bitzer J, Rahimi-Nedjat R, Taylor KJ (2014) Analysis of reasons for osteonecrosis of the jaws. Clin Oral Investig [Epub ahead of print]

  2. Pabst AM, Ziebart T, Koch FP, Taylor KY, Al-Nawas B, Walter C (2012) The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes—in vitro study. Clin Oral Investig 16:87–93

    Article  PubMed  Google Scholar 

  3. Hagelauer N, Pabst AM, Ziebart T, Ulbrich H, Walter C (2014) In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes. Clin Oral Investig [Epub ahead of print]

  4. Walter C, Laux C, Sagheb K (2014) Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study. Clin Oral Investig 18:385–390

    Article  PubMed  Google Scholar 

  5. Van Poznak C (2010) Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res Treat 122:189–191

    Article  PubMed Central  PubMed  Google Scholar 

  6. Koch FP, Walter C, Hansen T, Jäger E, Wagner W (2011) Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg 15:63–66

    Article  PubMed  Google Scholar 

  7. Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14:35–41

    Article  PubMed  Google Scholar 

  8. Walter C, Pabst A, Ziebart T, Klein MO, Al-Nawas B (2011) Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in-vitro. Oral Dis 17:194–199

    Article  PubMed  Google Scholar 

  9. Pabst AM, Ziebart T, Ackermann M, Konerding MA, Walter C (2013) Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay. Clin Oral Investig 18:1015–1022

    Article  PubMed  Google Scholar 

  10. Allegra A, Oteri G, Nastro E, Alonci A, Bellomo G, Del Fabro V et al (2007) Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 25:164–169

    Article  PubMed  Google Scholar 

  11. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M et al (2002) Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 8:1080–1084

    PubMed  Google Scholar 

  12. Ziebart T, Pabst A, Klein MO, Kaemmerer P, Gauss L, Bruellmann D et al (2011) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 15:105–111

    Article  PubMed  Google Scholar 

  13. Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E (2009) Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol 20:331–336

    Article  PubMed  Google Scholar 

  14. Williamson RA (2010) Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg 39:251–255

    Article  PubMed  Google Scholar 

  15. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE et al (2007) Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 65:1321–1327

    Article  PubMed  Google Scholar 

  16. Freiberger JJ (2009) Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67:96–106

    Article  PubMed  Google Scholar 

  17. Vescovi P, Manfredi M, Merigo E, Meleti M, Fornaini C, Rocca JP et al (2010) Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). Lasers Med Sci 25:101–113

    Article  PubMed  Google Scholar 

  18. Ziebart T, Koch F, Klein MO, Guth J, Adler J, Pabst A et al (2011) Geranylgeraniol – a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw. Oral Oncol 47:195–201

    Article  PubMed  Google Scholar 

  19. Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J et al (2010) Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 68:2837–2845

    Article  PubMed  Google Scholar 

  20. Ziebart T, Yoon CH, Trepels T, Wietelmann A, Braun T, Kiessling F et al (2008) Sustained persistence of transplanted proangiogenic cells contributes to neovascularization and cardiac function after ischemia. Circ Res 103:1327–1334

    Article  PubMed  Google Scholar 

  21. Crick DC, Andres DA, Waechter CJ (1997) Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem Biophys Res Commun 237:483–487

    Article  PubMed  Google Scholar 

  22. Walker K, Olson MF (2005) Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev 15:62–68

    Article  PubMed  Google Scholar 

  23. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW (2003) Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170:246–252

    Article  PubMed  Google Scholar 

  24. Iguchi K, Nakano T, Usui S, Hirano K (2006) Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells. Cancer Lett 237:223–233

    Article  PubMed  Google Scholar 

  25. Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR et al (2005) Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 11:206–213

    Article  PubMed  Google Scholar 

  26. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967

    Article  PubMed  Google Scholar 

  27. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M et al (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221–228

    Article  PubMed  Google Scholar 

  28. Aicher A, Kollet O, Heeschen C, Liebner S, Urbich C, Ihling C et al (2008) Wnt antagonist Dickkopf-1 mobilizes vasculogenetic progenitor cells via activation of the bone marrow endosteal stem cell niche. Circ Res 103:796–803

    Article  PubMed  Google Scholar 

  29. Shipman CM, Croucher PI, Russell RGG, Helfrich MH, Rogers MJ (1998) The bisphosphonate incardinate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58:5294–5297

    PubMed  Google Scholar 

  30. Coxon JP, Oades GM, Kirby RS, Colston KW (2004) Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 94:164–170

    Article  PubMed  Google Scholar 

  31. Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT (2002) Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62:2708–2714

    PubMed  Google Scholar 

  32. Hagelauer N, Ziebart T, Pabst AM, Walter C (2014) Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation. Clin Oral Investig [Epub ahead of print]

Download references

Conflict of interest

The authors declare that there is no conflict of interest. Christian Walter has received speaker fees from Roche and Riemser and funding from Novartis for a different study.

Role of funding source

None

Author information

Authors and Affiliations

  1. Department of Oral and Maxillofacial Surgery, University Medical Center Mainz, Augustusplatz 2, 55131, Mainz, Germany

    A. M. Pabst, M. Krüger, T. Ziebart & C. Walter

  2. Department of Orthodontics, University Medical Center Mainz, Augustusplatz 2, 55131, Mainz, Germany

    C. Jacobs

Authors
  1. A. M. Pabst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Krüger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Ziebart
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Walter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pabst, A.M., Krüger, M., Ziebart, T. et al. Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro. Clin Oral Invest 19, 1625–1633 (2015). https://doi.org/10.1007/s00784-014-1394-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00784-014-1394-z

Keywords

Search

Navigation